"Let food be your medicine, and let medicine be your food" Hippocrates (^^ - 500BC)
Nutri Pharma ASAKronprinsesse Marthas
Plass 1 P.O Box 1477, Vika N-0116 Oslo Norway Telephone +47 23 01 09 60 Telefax +47 23 01 09 70 Send e-mail |
Mandatory Notification of Trade19.11.2007 - Cleverling Business, a company controlled by Daniel Laroque - president of MIG and board member
of Nutri Pharma, has transferred a total of 200.000 shares...
Update - Meridian International Group (MIG)10.12.2007 - As previously reported, MIG has obtained a significant reduced cost structure,
including an improved B/E turnover....
Improved tax assessment14.11.2007 - In our stock exchange release of 14 February 2007 we informed that Nutri Pharma had received a draft proposal
from the tax authorities regarding change of the company`s tax assessments for the income years 2001-2003...
Mandatory Notification of Trade23.11.2007 - Cleverling Business, a company controlled by Daniel Laroque -president of MIG and board member of Nutri Pharma,
has transferreda total of 800.000 shares in Nutri Pharma....
New IT supplier in MIG, reduced operating cost12.11.2007 - An agreement has today been signed between Meridian International Group (MIG), wholly owned
subsidiary of Nutri Pharma ASA, Cleverling, controlled by the president of MIG and board
member in Nutri Pharma ASA, Daniel Laroque, and the former IT supplier Nexus, Meridian Art and
related parties...
Ekstraordinær Generalforsamling06.11.2007 - Styret innkaller med dette til ekstraordinær generalforsamling i Nutri Pharma ASA tirsdag 20.
november kl. 13 i selskapets lokaler i Kronprinsesse Märthas Plass 1...
Mandatory Notification of Trade24.08.2007 - Epsilon Eiendom AS, a company fully owned and controlled by CFO Lars H Enger and closely related family, has
today purchased400.000 NUT shares at NOK 3,2094 per share....
Mandatory Notification of Trade24.08.2007 - Project manager Hilde Aalling Syvertsen has today purchased 500.000 NUT shares at NOK 3,20 per share from Lars
Høie, board member of Nutri Pharma ASA....
Second Quarter 200723.08.2007 - Nutri Pharma today reports revenues of MNOK 19.0 million and a loss of MNOK 0.8 million for the
second quarter of 2007...
Nutrifemme marketing and sales team02.08.2007 - NutriFemme launch in Russia. The restructuring of the Russian operation is now showing results with record high
orders booked in July.
Nutri Pharma launch of Nutrifemme in Russia11.07.2007 - Nutri Pharma`s new female-health product will be launched as `NutriFemme` to the wholly-owned MIG direct marketing
network at the annual `Premium` event in Moscow in August...
Mandatory notification of trade25.04.07 - New board member in Nutri Pharma ASA Kristin Vestgren Sæterøy has today
purchased 500.000 NUT shares at NOK 2,74 per share from Lars Høie,
Board member of Nutri Pharma ASA...
First quarter 200724.05.2007 - Nutri Pharma (OSE: NUT) today reports revenues of MNOK 13, 5 million and a loss of MNOK 5,9 million for the first
quarter of 2007. This compares to revenues of MNOK 22,6 and a loss of MNOK 3,2 million in the first quarter of 2006...
New marketing director02.05.2007 - Nutri Pharma ASA has employed Käthe Eva Bleken as marketing director.
As the main task, Käthe will be in charge of the launch and commercialization of NUT`s female
health products, which treats symptoms related to menopause and PMS (pre-menstrual symptoms)....
Mottatt firmaattest27.04.2007 - Oslo Børs har mottatt firmaattest fra Nutri Pharma ASA i forbindelse med forhøyelse av aksjekapitalen. Se børsmelding
19.04.2007....
Meldepliktig handel20.04.2007 - Styremedlem i Nutri Pharma, Kristin Vestgren Sæterøy, har i dag 20.04.07 kjøpt 5.000 aksjer i
Nutri Pharma til kurs 3,23....
Primary insider purchase of shares19.04.2007 - Reference is made to the press release dated 19 April 2007 regarding the successfully completed
private placement in Nutri Pharma ASA....
Primary insider purchase of shares19.04.2007 - Reference is made to the press release dated 19 April 2007 regarding the successfully
completed private placement in Nutri Pharma ASA...
Successfully completed private placement19.04.2007 - Nutri Pharma ASA has on 18 April, 2007 successfully completed the private placement of a total of 7,865,000
new shares at a subscription price of NOK 3.10 per share.....
Planned private placement18.04.2007 - Nutri Pharma ASA has retained Orion Securities ASA to advise on and execute a private placement of new shares
directed towards professional Norwegian and international investors....
Annual general meeting18.04.2007 - General Meeting in Nutri Pharma ASA was held Wednesday 18 April 2007 at 10.00 hrs. All
items were resolved unanimously in accordance with the Boards Calling Notice...
Profit warning13.04.2007 - Based on preliminary reporting the revenues from the CIS region are expected to come in around 30% lower in Q1
2007 compared to Q4 2006.
Notice of Annual General meetingThe Annual general Meeting of Nutri Pharma ASA will be held Wednesday 18 April 2007, 10:00 a.m. at Hotel Continental, Stortingsgt.
24-26, 2 floor.
Approval of proposed annual accounts29.03.2007 - The Board of Directors of Nutri Pharma ASA has in a board meeting 29.03.2007 approved the final and audited accounts
for 2006.The final results have not changed since the release of the preliminary accounts for 2006....
EU legislation opens new markets for Nutri Pharma07.03.2007 - New EU legislation will enable companies who register a health claim made on food in one EU country to market
this food using the same health claim in any EU member state. Nutri Pharma has awaited this legislation as it provides opportunities
for companies who have made considerable investments in developing patented products with proven health benefits.
Mandatory notification of trade05.03.2007 - Lars H. Enger, ny CFO i Nutri Pharma ASA fra 1/5-07 har kjøpt 45.000 aksjer i NUT til NOK 3,35 per
aksje. Beholding etter kjøp: Epsilon Eiendom AS: 500.000 aksjer og Lars H Enger: 200.000 aksjer.
Mandatory notification of trade28.02.2007 - Epsilon Eiendom AS, a company fully owned and controlled by Lars H Enger and closely related
family, newly appointed CFO in Nutri Pharma ASA, has today purchased 500.000 NUT shares at NOK
2,88 per share from Lars Høie, Board member of Nutri Pharma ASA.
Fourth quarter and preliminary 2006 results27.02.2007 - Nutri Pharma today reports total revenue for 2006 of MNOK 82.8 compared to MNOK 25.3 in 2005. The loss in 2006
is MNOK 11.3 (MNOK -10.5 in 2005) after amortisation charges of MNOK 9.1. The EBITDA loss in 2006 is MNOK 2.9 compared to
a loss of MNOK 7.2 in 2005. Net financial revenue in 2006 is MNOK 0.7 compared to MNOK 0.1 last year.
Mandatory notification of trade21.02.2007 - Punto, a company fully owned and controlled by Haakon Ambjørndalen, advisor to Nutri Pharma ASA, has today sold
232.000 NUT shares ...
Tax assessment14.02.2007 - Nutri Pharma ASA has received a draft proposal from the tax authorities regarding change of the company`s tax
assessments for the income years 2001-2003....
Mandatory notification of trade06.02.2007 - Punto, a company fully owned and controlled by Haakon Ambjørndalen, advisor to Nutri Pharma ASA, has today sold
300.000 NUT shares at NOK 2,31 per share to Lars Høie, Board member of Nutri Pharma ASA.
Amendment of terms regarding acquisition of MIG05.02.2007 - Reference is made to previous communication regarding Nutri Pharma's acquisition of MIG and the terms therein.
The purchase consideration of 24 million NUT shares to be paid for the MIG shares that were transferred to Nutri Pharma ASA
on 1 July 2005 is regulated in the Share transfer agreement dated 1. June 2005 and Addendum 1 dated 12 September 2005.
Nutri Pharma research on the detrimental effects of UHT processing of Soy protein published17.01.2007 - A recently published placebo-controlled, randomised, double-blind clinical study over 4 weeks (80 persons) carried
out in conjunction with the Karolinska Institute in Stockholm and the University of Potsdam in Berlin has found that soy protein
products which have been UHT treated lose their ability to reduce serum cholesterol, and can significantly increase the levels
of harmful LDL cholesterol.
|